Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factorAnaïs Schavgoulidze, Jill Corre, Alexis Talbot et al.|Blood|2022Cited by 64
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical featuresTitouan Cazaubiel, Jill Corre, Xavier Leleu et al.|Blood|2022Cited by 30
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Jill Corre, Aurore Perrot et al.|Blood|2025Cited by 15
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myelomaGiulia Giorgetti, Michele Cea, Antonia Cagnetta et al.|Blood Cancer Journal|2025Cited by 3
Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment StrategiesGiulia Giorgetti, Michele Cea, Pamela Becherini et al.|Blood|2023Cited by 2